Assistant Director of the TRUST Program
Department of Radiology, UT Southwestern
While at UCSD, he designed and synthetized a novel MR contrast agent that incorporated gadolinium that was chelated and linked to hydrogel nanoparticles (nanogels). The advantage of this strategy is not only the development of high relaxivity T1 agents, but also minimizing demetallation. The versatility of this platform was demonstrated by incorporating 64Cu instead of gadolinium that allowed for in vivo PET/CT imaging of cancer. Dr. Lux also participated in the development of novel activatable optical nanoprobes for the detection of inflammation.
His current research interests lie in the development of novel nanomedicine platforms to diagnose and treat disease in vivo noninvasively with the long-term objective of developing clinically translatable theranostic agents. Dr. Lux received in November the 2017 Docstars Award by The Cary Council in recognition and support of promising early-stage research.